医学
单中心
淋巴瘤
阶段(地层学)
恶性肿瘤
乳腺癌
放射治疗
肿瘤科
内科学
放射科
癌症
古生物学
生物
作者
Sunil Iyer,Russ Kuker,Jorge A. Florindez,Eduardo Edelman Saul,Asaad Trabolsi,Gregor A. Rodriguez,Jennifer R. Chapman,Izidore S. Lossos,Juan Pablo Alderuccio
标识
DOI:10.1080/10428194.2021.1992764
摘要
Breast extranodal marginal zone lymphoma (EMZL) is a rare malignancy. We performed the largest published to date single-center retrospective analysis of 13 patients with breast EMZL focusing on clinical characteristics and treatment-related outcomes. The rarity of this disease at our center was concordant with the prevalence reported in the literature, with breast EMZL comprising 2% of 654 MZL cases. Most patients presented with stage I-II disease however four (30.8%) patients had stage IV disease mostly due to occult bone marrow (BM) involvement. Interestingly, EMZL was frequently non-FDG avid (66.7%) on staging PET/CT. With a median follow-up of 3.1 years (range 5 months to 10.2 years), the 3-year progression free survival was 68.7% (95%CI 30.2%-88.9%) and overall survival 80.2% (95%CI 40.3%-94.8%). No patient experienced higher-grade transformation. Herein we show that localized breast EMZL can be effectively treated with radiation therapy providing long term disease control.
科研通智能强力驱动
Strongly Powered by AbleSci AI